Woman Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Phase 1b - to determine the recommended Phase 2 dose of LY2228820 that can be safely administered with gemcitabine and carboplatin Phase 2 - to compare the progression-free survival in patients treated with LY2228820 plus gemcitabine and carboplatin versus placebo plus gemcitabine and carboplatin
Inclusion criteria
- Epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer